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nose in all patients and the larynx in fewer patients, and less often the trachea and bronchi.
Study design: Analysing the clinical and imaging data of 48 patients’ scleroma.
Results: Forty-eight scleroma patients were included. Their age ranged from 17 to 60 years.
There was female predominance. Patients presented with laryngeal and tracheal symptomatologies
were more common than nasal symptomatology. Combined nasal with laryngeal affection exhibited
the most frequent occurrence. Radiologically, a new pattern of involvement of the trachea ﬁts the
description of cribriform tracheitis. The commonest naked eye appearance was ﬁbrosis, granuloma
and to a lesser extent atrophy and crusting.
Conclusion: A change in the pattern of presentation and regional involvement in scleroma dic-
tated the need for a change of its name and our awareness.
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Scleroma is a speciﬁc, chronic granulomatous condition of the
upper respiratory tract that particularly affects the nose, clas-Ear, Nose, Throat and Allied
evier B.V. All rights reserved.
yptian Society of Ear, Nose,
lsevier
(Z. Mandour).sically, in all patients and the larynx in fewer patients, and less
often the trachea and bronchi.1
Because of the preponderance of cases with nasal involve-
ment, earlier papers reported the disease as rhinoscleroma
(RS). While most patients do, indeed present with nasal
involvement, the pharynx is involved in more than half the
cases.1 In Mexico, laryngeal scleroma was evident in 15% of
patients with scleroma, with tracheal and bronchial involve-
ment occurring in 2% of their cases.2 Unusual presentations
of scleroma are reported in the literature. The youngest age
reported was in a newborn infant, with affection of his middle
ear. The oldest age reported was in a man of 68 years with the
involvement of paranasal sinuses.3 Cervical lymph node
involvement has been recorded.4 Scleroma has showed intra-
cranial extension,5,6 and malignant transformation.7 The
report of Lasanga8 on an Italian family in which 15 persons
suffered from scleroma and that of Hara et al.9 with scleroma
documented in seven cases in a family in the United States,
where the disease is rarely seen, is still of great interest.
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Ciproﬂoxacin,11 Ceforanide,12 Rrifampicin13 Fluoroquino-
lone,14 Trimethoprim Sulphametaxazole15 and Streptomy-
cin.16 These medications have found to be effective only after
prolonged treatment.17 Surgery and CO2 laser are used for
debulking in the granulomatous stage or in airway widening
after the ﬁbrotic or cicatricial stage.18
Patients must be clinically and histologically free of disease
and have negative tissue cultures; otherwise the risk of recur-
rence or dissemination is substantial.7
Scleroma should be considered in the differential diagnosis
of granulomatous and neoplastic diseases that affect the nose
or the facial midline granulomas, including the lips and the
hard or the soft palate.7
In the last decade, changes in the presentation of the scle-
roma patients are observed in our institute, which dictated a
change in its management.
2. Aim
Study of patients presented with scleroma of the respiratory
tract in a period of 5 years considering patients’ demography,
symptomatology, regional affection and naked eye appearance
of their lesions and report of the experience of new radiological
observations and the application of non-conventional regimen
in its treatment.
3. Patients and methodology
From 1st January 2005 to the end of December 2009, 48 pa-
tients with histologically documented scleroma presenting to
the outpatient department of ORL department at the Main
University Hospital (MUH), of the Faculty of Medicine, Uni-
versity of Alexandria, Egypt were reviewed as regards their:
X Demographic data (sex and age).
X Full history taking and clinical examination.
X Outpatient nasal and laryngeal endoscopy.
X Multislice CT scans and virtual endoscopy of the upper and
lower airway.
X Documentation of the different lesions reported and their
naked eye appearances (N.E.A.) identiﬁed.
X Intra-operative direct micro-laryngoscopy and bronchos-
copy under general anaesthesia for cases with laryngeal
and or tracheal involvement.
X All patients were treated according to the following regimen:
o Nasal lesions:
 Crusting: nasal irrigation with Modiﬁed Wilson’ solution
(garamycin 16% in saline).
 Fibrotic stage with obstruction: vestibulotomy with stenting.
o Laryngeal and tracheal lesions:
 Granulomatous stage with minimal airway obstruction:
levoﬂoxacin and inhalational mitomycin-C.
 Granulomatous or ﬁbrotic stage with air way obstruc-
tion: CO2 laser debulking followed by levoﬂoxacin and
inhalational mitomycin-C.
X Inhalational mitomycin regimen: 0.5 ml containing 0.5 mg
mitomycin C diluted in 2 ml of 0.9% saline, delivered
through an electronic nebulizer; eight hourly on the ﬁrst
week then 12 hourly on the second and third weeks thenonce every evening. The once daily dose will continue until
total disappearance of the granulomatous lesions and/or
mucosal healing, especially after laser.
X Levoﬂoxacin regimen: The patient started on 750 mg daily
for 10 days then 500 mg daily until mucosa returns to its
normal colour. Then, the patient was maintained on
250 mg until the airway returns to normal or ﬁbrosis
becomes established.
X Complete blood picture, blood urea and creatinine, liver
function and chest X-ray was repeated every 2–4 weeks to
check for any affection of the patient’s well being as a result
of the regimens applied (Appendix 1).
X All the data collected were compared using S.P.S.S. version
11.
X The ethics committee of Alexandria Medical School
approved the study and informed consents signed by all
patients.
4. Results
Forty-eight histo-pathologically documented scleroma patients
were studied. There were 20 males and 28 females. Their age
ranged from 17 to 60 years with a mean of 39.04 + 10.5 years.
Clinically, patients presented with laryngeal and tracheal
symptomatology in 71% (34 out of 48 cases), 64.7% (22 out
of 34 cases) with hoarseness and 35.3% (12 out of 34 cases)
with stridor (Figs. 1 and 2). Nasal presentation was found in
29% (14 out of 48 cases), 57.1% (8 out of 14 cases) with nasal
obstruction, 28.6% (4 out of 14 cases) with nasal crusting, and
in 14.3% (2 out of 14 cases) with nasal offensive discharge
(Fig. 3).
The nose was solely affected in 25% (12 out of 48 cases).
Combined nasal affection with other regional involvement,
was most frequently encountered with the larynx in 65% (30
out of 48 cases) followed by the trachea in 52% (25 out of
48 cases), and less commonly the palate was affected by ﬁbro-
sis in 14.5% (7 out of 48 cases) while only 2% (1 out of 48 case)
showed tonsillar affection.
The commonest naked eye appearance (NEA) was ﬁbrosis
in 41.6% (20 out of 48 cases) which commonly affected the tra-
chea in the form of cribriform appearance on CT scan and
mesh of ﬁbrosis on endoscopy. Granuloma was found in
31.2% (15 out of 48 cases) which commonly affected the lar-
ynx, while atrophy and crusting presented in 10.5% (5 out of
48 cases). Combined granulomatous and atrophic appearance
was encountered in 16.7% (8 out of 48 cases).
Histopathological examination of biopsied tissue showed
Klibsiella rhinoscleromatis bacilli and the characteristic
Mikulicz cells (Fig. 4).
Levoﬂoxacin was used for all patients for on average
6.3 + 0.58 months to obtain what was appreciated as disease
quiescence/arrest. On follow-up, 25 cases (52%) showed recur-
rence after 6 months to one year of cessation of treatment. Inha-
lational mitomycin was used for an average of 5.5 + 2.5 weeks
for the treatment of primary granulomatous lesions or after la-
ser surgery. Repeated blood tests and chest X-rays during the
use of both regimens did not signal the need for cessation of
drugs at any time or in any patient.
All obstructing laryngotracheal lesions (14 out of 25 tracheal
cases [56%] and 19 out of 30 laryngeal cases [63%]) were treated
Figure 1 (A–D): Laryngotracheal involvement & resolution (A) Showing endoscopic laryngeal (glottic and subglottic) view in a 60-year-
old 135 kg diabetic female with concentric granulomatous narrowing which was documented by CT Scans (B) with 2 weeks and 9 months
(C and D) after inhalational mitomycin-C and levoﬂoxacin. Residual concentric ﬁbrosis of the upper trachea is quite evident.
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by mytomycin-C inhalation treatment. No recurrence was ob-
served within the cribriform tracheitis group after 3 years of
close follow up, while all granulomatous lesions tend to recur
after surgical removal after one year of medical treatment stop-
page. Two out of 45 cases of laryngotracheal scleroma (4.5%)
needed tracheostomy to relieve airway obstruction. Both of
them were successfully decannulated after laser therapy. As re-
gards ﬁbrotic obstructing of nasal lesions, vestibulotomy with
stenting was done in four cases only (8%). The ﬂow chart for
the management of rhinoscleroma patients is summarized in
Appendix 1.
5. Discussion
Scleroma is a chronic granulomatous disease caused by Klebsi-
ella rhinoscleromatis. It is endemic in Africa, Central and South
America, South Central and Eastern Europe, the Middle East,
and China.19–21 The ﬁrst historic evidence of patients with scle-
roma was in a Mayan Indian terracotta head dated between
300 and 600 AD depicting typical nasal proliferative lesions
of this disease.22,23
Hebra and Kohn24 in 1870 ﬁrst described the condition as
‘‘scleroma’’ or ‘‘rhinoscleroma’’ and considered it as neoplastic
growth. Gerber25 ﬁrst suggested the inﬂammatory nature of
scleroma. Mikulicz26 in 1877 described the typical foamy cells
identiﬁed in biopsy specimens. Von Frisch27 isolated K. rhi-
noscleromatis (KR) in 1882.At the International Congress of Otolaryngology in 1932,
Belinoff28 proposed the term scleroma respiratorium for this
condition because not only the nose and upper respiratory air-
ways are involved, but also there was affection of the lower
respiratory tract. However, at the same congress he recognized
that even though scleroma is a more proper term for this dis-
ease, the preﬁx ‘‘rhino’’ should not be eliminated from either
the name or the causative microorganism.29
The ﬁrst or exudative stage is characterized by mucosal
congestion, rhinitis with suppurative discharge, and ﬁnally
nasal obstruction. During the second or proliferative stage,
the typical nodules and inﬁltrative granulomas develop.30
The ﬁnal or cicatricial stage is characterized by extensive scar-
ring. An atrophic phase between the ﬁrst and second stages has
been described.31–34
The present ﬁndings showed that both sexes are almost
equally affected with a small predilection for women
(p= 0.82).Most patients affectedwith the disease seemed to be-
long to the lower economic class andhadpoor nutritional status.
The age in the present series were on average slightly higher
than the reported one elsewhere, which may be related to the
older age group of our patients. According to the literature,
the affected patients were usually between 15 and 35 years of
age.34 Lesions are rarely regressing spontaneously; however,
episodes of remission and relapse are quite common.35
We found a high laryngeal and tracheal symptomatology
and clinical affection have not been previously reported,
according to the most recent knowledge.
Figure 2 (A–D): Cribriform trachea showing concentric tracheal narrowing by a mesh-like ﬁbrous strand, crossing from one side to the
other, giving the cribriform appearance. (A) and (B) show multi-slice CT scan appearance with its virtual endoscopy on (C), while (D) is
the endoscopic view. Virtual endoscopy showed the cribriform pattern as nodularity only.
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initial symptom in 94% of cases is nasal obstruction followed
by nasal deformity in 32%. Interestingly, 10% of the lesions
started as a swelling of the upper lip. The same study showed
that the palate is affected in 31% of cases. The soft palate is
more frequently involved than the hard palate. The upper lip
ranks ﬁfth (12% of cases). When the hard palate is affected,
there is bone destruction produced by a progressive nodular
inﬁltrate.36 The nodular inﬁltration in the soft palate extends
to the tonsillar fossa and oropharynx. Eventually, scarring
can lead to forward tilting of the uvula and ﬁbrous steno-
sis.19,37 Regarding our series, the palate was affected by ﬁbro-
sis in 14.5% (seven cases) while only 2% (one case) showed
tonsillar affection.
Soni38 found in his series of 20 patients with rhinoscleroma,
eight cases (40%) with laryngeal involvement, four cases
(20%) suffering from tracheal lesions and only one case with
bronchial involvement. The intranasal lesion, endotracheal
and endobronchial lesions all occurred in the form of an
atrophic stage, granulomatous (proliferative) stage and ﬁnally
a ﬁbrotic or scarring stage.38 In addition, isolated bronchial
scleroma was detected in the Acuna39 series in 1973 and oth-
ers.40,41 In other reports, the incidence of laryngeal involve-
ment in scleroma varied from 15% to 80%,38,42,43 but
tracheobronchial involvement was far less common. A reportfrom the United States showed that 13 of 22 patients with
rhinoscleroma had laryngotracheal scleroma (LTS); nine had
subglottic stenosis and/or glottic stenosis, and only 2 out of
22 cases had tracheal involvement limited to the ﬁrst two tra-
cheal ring.42 Gaafar44 described the endoscopic pattern of LTS
in 11 patients; laryngeal involvement was diffuse and localized,
tracheal lesions appeared granular or atrophic, and bronchial
involvement caused bronchial narrowing. Another group from
New York recently reported a case of LTS diagnosed by PET-
CT scan where the lesion was nodular all through the whole
lower respiratory tract and was treated by argon debulking fol-
lowed by levoﬂoxacin 500 mg daily.45
The latter literature tended to indicate the uncommon
involvement of the lower respiratory contrary to the present
study at hand. Either it is a change of disease pattern due to
the more frequent availability of health care system, or due to
the application of advanced radiological technology or even
both. Actually, the occurrence of tracheal involvement expected
by the biphasic stridor and the minimal subglottic region affec-
tion in one of our patientsweremissed by conventional neckCT.
Multislice CT exhibited cribriform tracheal involvement that
was documented by endoscopy. The latter cribriform pattern
of the trachea has not been previously reported.
According to our series, the main lines of treatment were
levoﬂoxacin, and inhalational mitomycin-C, assisted by CO2
Figure 3 Nasal involvement showing nasal crusting and ﬁbrosis documented by endoscopic view (A) as well axial and coronal CT scans
opaciﬁcation of the nasal cavity (B–D).
Figure 4 (A) Silver methenamine showing rod-shaped bacilli within the histiocytes (·150). (B) Warthin–Starry stain showing rod-shaped
bacilli in the cytoplasm of Mikulicz histiocytes (·250).
Scleroma: New patterns and approaches to an old disease 137laser debulking or ﬁbrolysis when indicated. Levoﬂoxacin as a
single daily dose medication provided rapid disease control. Its
long term use has been approved by the WHO46 in 1997 and
conﬁrmed in 200247 and re-afﬁrmed in 201048 with an overall
complication rate of less than 1.6%. It has been used for the
ﬁrst time in the treatment of K. rhinoscleromatis bacteraemiain the USA in 2007.49 A year later, Talwar et al. from New
York treated a case of nodular inﬁltration of the laryngo-tra-
cheobronchial airway by levoﬂoxacin after argon laser debul-
king. The use of levoﬂoxacin for extended periods of over
several months for a good number of patients has proven to
be safe, until now, in all of our patients.
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experimental animals,50 has no granuloma reaction especially
in the trachea and larynx whether the patient was debulked or
not. It proved to be an effective tool thatmaintained disease qui-
escence and helped induce mucosal healing. Inhalational mito-
mycin-C delivered through an electronic nebulizer, facilitates
its repeated application to the upper and the lower respiratory
tract on a regular basis, as well as its even distribution without
the need for repeated hospital admissions or anaesthesia.
The name ‘‘respiratory scleroma’’ is preferred over the term
rhinoscleroma because this disease not only affects the nose
but also the respiratory tract in addition to the oropharynx.
Regions affected other than respiratory tract may refer to
‘‘Para-respiratory scleroma’’.
6. Conclusion
 There is a change in the pattern of presentation and the
regional involvement in scleroma. The latter ﬁndings
emphasize the recommendation of the use of ‘‘respiratory
scleroma’’ as the correct terminology that entailed the dis-
ease presentation and its regional involvement with accu-
racy. The term Para-respiratory scleroma has also been
suggested describing scleroma elsewhere.
 CT scan is helpful in the diagnosis of scleroma especially in
ﬁbrotic tracheal lesions where it manifests the characteristic
cribriform appearance.
 New modalities in medical and surgical treatment have to
gain high priority in scleroma management. Inhalational
mitomycin-C was found to be very effective in reducing
the recurrence of laryngotracheal ﬁbrosis, and to a lesser
extent, granulomas after laser treatment.Appendix A
Summary. tables
 Forty-eight rhinoscleroma patients were included in our
study.
 Both sexes were equally affected with a small predilection
for women.
 The most commonly encountered symptoms were hoarse-
ness of voice and stridor.
 Nose was solely affected in 25% of cases.
 The most frequently-affected region regarding combined
nasal affection compared with other regional affection
was the larynx followed to a lesser extent by the trachea.
 The commonest naked eye appearance affecting the larynx
was ﬁbrosis followed by granulomas and to a lesser extent
by atrophy and crusting.
 The trachea was commonly affected by ﬁbrosis, which
exhibited cribriform in appearance on CT scan and mesh
of ﬁbrosis on endoscopy.
 The commonest nasal naked eye appearance affection was
ﬁbrosis.
 Multi-slice CT exhibited cribriform tracheal involvement.References
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